Nuvectis Pharma, Inc. NVCT R2K
Healthcare · Biotechnology · United States
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
READ MORE ›$9.75
+3.61% 1Y
Market & Price
Market Cap
$258.62M
Current Price
$9.75
High / Low (52W)
$12.45 / $5.65
Beta
-0.12
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.54
Price to Book
18.19
P/S
-
EV/EBITDA
-
Dividend Yield
-
Profitability & Returns
ROCE
-149.75%
ROE
-
ROA
-63.61%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.26
EPS (TTM)
$-1.31
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
2.25
Current Ratio
2.27
Debt
$0
Total Assets
$31.71M
Current Assets
$31.71M
Working Capital
$18.41M
Ownership
Promoter Holding
41.61%
Chg in Prom Hold
-
FII / Inst Holding
18.23%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$233.49M
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
$-9.17M
Operating Cash Flow
$-18.35M
Shares Outstanding
26.53M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-12.85%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -12.8% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NVCT Nuvectis Pharma, Inc. R2K | 9.75 | - | $258.62M | - | -149.75% | - | - | -12.85% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 5.57M | 6.59M | 7.79M | 7.62M | 6.26M |
| Operating Income | -23.00K | -5.94M | -4.67M | -2.94M | -3.57M | -5.94M | -4.10M | -5.77M | -6.16M | -4.40M | -4.64M | - | -5.57M | -6.59M | -7.79M | -7.62M | -6.26M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -5.57M | -6.59M | -7.79M | -7.62M | -6.26M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -23.00K | -5.94M | -4.67M | -2.94M | -3.57M | -5.88M | -4.05M | -5.71M | -5.88M | -4.17M | -4.43M | - | -5.33M | -6.33M | -7.46M | -7.31M | -6.05M |
| Diluted EPS | 0.01 | -1.43 | -1.04 | -0.32 | -0.28 | -0.42 | -0.27 | -0.38 | -0.37 | -0.25 | -0.26 | -0.24 | -0.27 | -0.30 | -0.44 | - | -0.26 |
| R&D Expense | - | 4.25M | 4.16M | 1.80M | 2.50M | 4.52M | 2.37M | 4.26M | 4.49M | 2.66M | 2.94M | 2.82M | 3.68M | 3.61M | 5.77M | - | 4.11M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 19.23M | 22.90M | 19.85M | 27.57M |
| Operating Income | - | -19.23M | -22.90M | -19.85M | -27.57M |
| EBITDA | - | -19.23M | -22.90M | -19.85M | -27.57M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -19.09M | -22.26M | -19.00M | -26.44M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -19.09M | -22.26M | -19.00M | -26.44M |
| Diluted EPS | -1.09 | -1.51 | -1.43 | -1.11 | - |
| R&D Expense | 9.54M | 13.23M | 15.38M | 12.92M | 18.15M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -12.85% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +3.61% |
| 6 Months: | +60.10% |
| 3 Months: | +10.05% |
| 1 Month: | +14.71% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 20.41M | 19.18M | 18.61M | 31.71M |
| Current Assets | - | - | 20.41M | 19.18M | 18.61M | 31.71M |
| Cash & Equivalents | - | - | 19.99M | 19.13M | 18.53M | 31.63M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Total Liabilities | - | - | 6.19M | 6.98M | 8.89M | 13.30M |
| Current Liabilities | - | - | 6.19M | 6.98M | 8.89M | 13.30M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - |
| Total Equity | -10.00K | - | 14.22M | 12.20M | 9.71M | 18.41M |
| Shares Outstanding | - | - | 14.64M | 17.42M | 19.50M | 25.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -13.56M | -15.95M | -12.25M | -16.01M |
| Investing Cash Flow | - | 0 | 0 | 0 | 0 |
| Financing Cash Flow | - | 27.81M | 15.09M | 11.65M | 29.11M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | -13.56M | -15.95M | -12.25M | -16.01M |
| Net Change in Cash | - | 14.25M | -867.00K | -593.00K | 13.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -134.2% | -182.4% | -195.6% | -143.6% |
| ROCE % | - | -135.3% | -187.7% | -204.3% | -149.8% |
Shareholding Pattern
Insiders
41.61%
Institutions
18.23%
Public Float
31.21%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 2.88% | 764.44K | $7.45M |
| 2 | Vanguard Capital Management LLC | 2.49% | 659.88K | $6.43M |
| 3 | Iridian Asset Management LLC | 2.46% | 651.76K | $6.35M |
| 4 | Occam Crest Management LP | 1.53% | 407.15K | $3.97M |
| 5 | Geode Capital Management, LLC | 1.45% | 384.11K | $3.75M |
| 6 | Baldwin Wealth Partners LLC/MA | 1.43% | 378.62K | $3.69M |
| 7 | State Street Corporation | 0.63% | 166.52K | $1.62M |
| 8 | Northern Trust Corporation | 0.47% | 124.21K | $1.21M |
| 9 | Vanguard Fiduciary Trust Co | 0.43% | 114.84K | $1.12M |
| 10 | Susquehanna International Group, LLP | 0.40% | 105.29K | $1.03M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVCT
No recent headlines available.